The purpose of this study is to evaluate the clinical effectiveness and safety of torsemide compared to furosemide combined with concurrent therapy (pimobendan, spironolactone, and an ace inhibitor) for the management of pulmonary edema in dogs with CHF caused by MMVD.
Dogs with degenerative mitral valve disease are at increased risk to develop congestive heart failure in which fluid accumulates in the lungs making it difficult to breath. Treatment of CHF includes the use of diuretics which are drugs that help the body eliminate excessive fluid. The current standard of care is a drug called furosemide, which is given 2 to 3 times a day. Torsemide is similar to furosemide but has the advantage of just once daily dosing which is easier and more convenient to manage.
Potentially eligible dogs will have up to 21 days from entering CHF to be screened.
Eligible dogs must be free of congenital heart conditions and significant systemic disease.
Dogs enrolled will come to Penn Vet for scheduled study visits over the course of a 3-month enrollment period. While enrolled, owners will be required to make daily recordings in a logbook documenting details about their dog’s symptoms and medication administration.
All study related costs are covered including:
- Physical exams
- Lab work
- Study treatment
- Radiographs
- Echocardiogram
Contact the Veterinary Clinical Investigations Center (VCIC) at 215-573-0302 or vet-vcic@vet.upenn.edu